In Reply Raghav and Strickler raise 3 major questions in their response to our article1: (1) was the survival effect in the HERACLES study determined by anti-EGFR or by chemotherapy? (2) was ERBB2 amplification (referred to as “HER2-amplification” in our article, but herein referred to as “ERBB2-amplification”) high enough in those patients deriving a benefit from anti-EGFR therapy? (3) is ctDNA analysis reliable when testing for ERBB2 amplification?